Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KLK1 | P06870 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369349 | 0.89 | L3MBTL1 (0.58) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| SCHEMBL17454410 | 0.89 | L3MBTL1 (0.58) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| SCHEMBL2272882 | 0.87 | L3MBTL1 (0.57) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL31549317 | 0.87 | L3MBTL1 (0.57) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| SCHEMBL17895755 | 0.87 | L3MBTL1 (0.60) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| SCHEMBL2511099 | 0.86 | L3MBTL1 (0.56) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| SCHEMBL17801300 | 0.86 | L3MBTL1 (0.56) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| SCHEMBL369195 | 0.85 | GSK3B (0.55) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| SCHEMBL17452635 | 0.85 | L3MBTL1 (0.55) | L3MBTL1KLKB1MEN1KMT2ANPC1 | |
| SCHEMBL2511098 | 0.85 | L3MBTL1 (0.55) | L3MBTL1KLKB1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2024-10-29 | — | — | US | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| EP-3712153-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3712153-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-109071546-B | Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors | 辉瑞大药厂 | 2021-03-02 | — | — | CN | disclosed |
| EP-2593277-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2324024-B1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2324024-B1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| WO-2012009000-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| EP-2324024-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2009151589-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151589-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | CBR3, CNR1, CBR1 | L3MBTL1 1343/4885KLKB1 4845/4885MEN1 2497/4885 |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | L3MBTL1 1530/4885KLKB1 4840/4885MEN1 2257/4885 |
| US-20110124654-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | L3MBTL1 2908/4885KLKB1 1089/4885MEN1 1132/4885 |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | SYMPK, IL15, STAT6 | L3MBTL1 2811/4885KLKB1 468/4885MEN1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.